triple agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-15. Numbers and descriptions here follow the published literature rather than marketing material.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
The live album Radical Action to Unseat the Hold of Monkey Mind, was released in September 2016, drawing from 2015 concert dates of Japan, Canada and France featuring Rieflin. A 4-disc set aimed at documenting the band's ever-evolving live setlist, it included one performance of every song the band presented onstage during the tour and concert footage mostly recorded in Takamatsu, Japan, on 19 December 2015. On 7 December 2016, founding King Crimson member Greg Lake died of cancer. Another former King Crimson member, John Wetton, died of colon cancer on 31 January 2017. On 3 January 2017, Rieflin returned to King Crimson. Since the band also wished to retain Stacey, King Crimson became an octet, which Fripp initially referred to as the "Double Quartet Formation". Rieflin later eschewed drumming with the group and became King Crimson's first full-time keyboardist, with Fripp rechristening the line-up the "Three Over Five" (or "Five Over Three") formation. On 2 June 2017, King Crimson released a new live EP named Heroes, featuring a cover of the David Bowie song of the same name. The EP was intended as a tribute to Bowie, for whom Fripp had provided distinctive guitar work on the albums "Heroes" (1977) and Scary Monsters (and Super Creeps) (1980). The video for King Crimson's version of "Heroes" won "Video of the Year" at the 2017 Progressive Music Awards. Shortly afterwards, King Crimson embarked on the first leg of a North American tour, from 11 June until 19 July.
Haber's new unit was called Pioneer Regiment 35. After brief training in Berlin, Hahn, together with physicists James Franck and Gustav Hertz, was sent to Flanders again to scout for a site for a first gas attack. He did not witness the attack because he and Franck were off selecting a position for the next attack. Transferred to Poland, at the Battle of Bolimów on 12 June 1915, they released a mixture of chlorine and phosgene gas. Some German troops were reluctant to advance when the gas started to blow back, so Hahn led them across No Man's land. He witnessed the death agonies of Russians they had poisoned, and unsuccessfully attempted to revive some with gas masks. On their next attempt on 7 July, the gas again blew back on German lines, and Hertz was poisoned. This assignment was interrupted by a mission at the front in Flanders and again in 1916 by a mission to Verdun to introduce shells filled with phosgene to the Western Front. Then once again he was hunting along both fronts for sites for gas attacks. In December 1916 he joined the new gas command unit at Imperial Headquarters. Between operations, Hahn returned to Berlin, where he was able to slip back to his old laboratory and work with Meitner, continuing with their research. In September 1917 he was one of three officers, disguised in Austrian uniforms, sent to the Isonzo front in Italy to find a suitable location for an attack, using newly developed rifled minenwerfers that simultaneously hurled hundreds of containers of poison gas onto enemy targets.
=== Side-effects === Although patients at high risk of bleeding were excluded from the phase III clinical study (PROWESS), 25% of patients treated with drotrecogin and 18% of those receiving placebo experienced at least one bleeding event (principally ecchymoses or GI bleeding) during the 28-day study period. During treatment, serious bleeding events (e.g., intracranial hemorrhage, any life-threatening bleeding event, any bleeding event requiring administration of at least 3 units of packed red blood cells daily for 2 consecutive days) occurred in 2.4% of patients treated with drotrecogin and in 1% of those receiving placebo. No significant differences between geriatric patients and younger patients regarding bleeding events in the drotrecogin group were found. No non-bleeding side-effects were observed. A second study, encompassing approximately 1700 adult patients, was completed in 2011 and showed a comparable side-effect profile.
In July 2018, the Food and Drug Administration approved enzalutamide, developed by Pfizer and Astellas Pharma for patients with castration-resistant prostate cancer. In August 2018, Pfizer signed an agreement with BioNTech to conduct joint research and development activities regarding mRNA-based influenza vaccines. In October 2018, effective January 1, 2019, Albert Bourla was promoted to CEO, succeeding Ian Read, his mentor. In July 2019, the company acquired Therachon for up to $810 million, expanding its rare disease portfolio through Therachon's recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as achondroplasia. Also in July, Pfizer acquired Array Biopharma for $10.6 billion, boosting its oncology pipeline. In August 2019, Pfizer merged its consumer health business with that of GlaxoSmithKline, into a joint venture owned 68% by GlaxoSmithKline and 32% by Pfizer, with plans to make it a public company. The transaction built on a 2018 transaction where GlaxoSmithKline acquired Novartis' stake in the GSK-Novartis consumer healthcare joint business. The transaction followed negotiations with other companies including Reckitt Benckiser, Sanofi, Johnson & Johnson, and Procter & Gamble. In September 2019, Pfizer initiated a study with the CDC Foundation to investigate the tracking of healthcare-associated infections, scheduled to run through to June 2023. In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its cryptococcal disease screening and treatment research in nine African countries.
Strigolactones (SLs) were originally discovered through studies of the germination of the parasitic weed Striga lutea. It was found that the germination of Striga species was stimulated by the presence of a compound exuded by the roots of its host plant. It was later shown that SLs that are exuded into the soil also promote the growth of symbiotic arbuscular mycorrhizal (AM) fungi. More recently, another role of SLs was identified in the inhibition of shoot branching. This discovery of the role of SLs in shoot branching led to a dramatic increase in the interest in these hormones, and it has since been shown that SLs play important roles in leaf senescence, phosphate starvation response, salt tolerance, and light signalling.
Sources: en.wikipedia.org
Polish refugees were housed at dedicated settlements set up at Marandellas and Rusape, two towns about 40 km (25 mi) apart to the south-east of Salisbury, from 1943. There were similar camps in Kenya, Nyasaland, Tanganyika, Northern Rhodesia and South Africa. The Polish settlements in Southern Rhodesia were run jointly by local authorities and the Polish consulate in Salisbury; the Polish government-in-exile in London provided funding. Transport back to Europe picked up sharply as the war came to a close, and by October 1945 less than 2,000 Polish refugees remained. Colonial officials were reluctant to let the Poles stay indefinitely, asserting that they were not culturally British enough and might have communist connections or sympathies, but most of those who remained showed little inclination to leave. Southern Rhodesia ultimately allowed around 726 Polish refugees to settle permanently after the war.
The first Waffle House opened on Labor Day weekend in 1955 at the location 2719 East College Avenue in Avondale Estates, Georgia. That restaurant was conceived and founded by Joe Rogers Sr. and Tom Forkner. Rogers started in the restaurant business as a short-order cook in 1947 at the Toddle House in New Haven, Connecticut. By 1949, he had become a regional manager with the now-defunct Memphis-based Toddle House chain. He then moved to Atlanta, where he met Tom Forkner while buying a house from him in Avondale Estates. Rogers's concept was to combine the speed of fast food with table service with around-the-clock availability. Forkner suggested naming the restaurant "Waffle House", as waffles were the most profitable item on the 16-item menu. Rogers continued to work with Toddle House, and, to avoid conflict of interest, sold his interest to Forkner in 1956.
=== Therapeutics === The small size and stability profile of Affimers combined with their human origin confer drug-like properties. This may represent advantages over antibodies in terms of tissue penetration, for example in solid tumours where Avacta are developing PD-L1 inhibitors as alternatives to Opdivo and Yervoy, though requires half life modification to prevent rapid excretion through the kidney. Affimers can be conjugated to form multimers for the design of therapeutics. Examples include the production of multi-specific Affimer molecules to albumin binders to increase their half-life in vivo and for use as the targeting moiety in chimeric receptors or modified to carry a toxin in Affimer-drug conjugates. Affimers as therapeutics are in discovery and preclinical development to tackle cancer, both via CAR-T cell therapy and as checkpoint inhibitors. Early studies using ex vivo human samples showed low immunogenicity associated with the Affimer scaffold, at levels comparable to a marketed antibody therapeutic. Furthermore, initial preclinical studies showed good efficacy and tolerability of the anti-PDL1 immuno-oncology Affimers in mice. It is anticipated that IND filing for the first Affimer therapeutic will occur in 2023.
Alexander Fleming discovered the world's first antibiotic, penicillin, which Florey and Chain then developed. Gerhard Domagk developed sulphonamides, the first broad spectrum synthetic antibacterial drugs.
Sources: en.wikipedia.org
government experiment that infected hundreds of Guatemalans with syphilis". A previous suit against the United States government was dismissed in 2011 for the Guatemala syphilis experiments when a judge determined that the U.S. government could not be held liable for actions committed outside of the U.S. An experiment was conducted by Vanderbilt University in the 1940s where they gave 800 pregnant women radioactive iron, 751 of which were pills, without their consent. In a 1969 article published in the American Journal of Epidemiology, it was estimated that three children had died from the experiment.
mitotic recombination Also somatic crossing over. The abnormal exchange of genetic material between homologous chromosomes during mitosis (as opposed to meiosis, where it occurs normally). Homologous recombination during mitosis is relatively uncommon; in the laboratory, it can be induced by exposing dividing cells to high-energy electromagnetic radiation such as X rays. As in meiosis, it can separate heterozygous alleles and thereby propagate potentially significant changes in zygosity to daughter cells, though unless it occurs very early in development this often has little or no phenotypic effect, since any phenotypic variance shown by mutant lineages arising in terminally differentiated cells is generally masked or compensated for by neighboring wild-type cells.
Blotting is frequently necessary when using dip pens and occasionally when using fountain pens. This was first done by sprinkling pounce over the wet ink. When used to remove ink, the writing may appear in reverse on the surface of the blotting paper, a phenomenon which has been used as a plot device in a number of detective stories, such as in the Sherlock Holmes story "The Adventure of the Missing Three-Quarter".
In Donetsk Oblast, Russian forces claimed to have taken control of the villages of Novooleksandrivka, northwest of Ocheretyne, and Spirne, near the border with Luhansk Oblast. One person was killed in a Russian airstrike in Kharkiv. The Russian defence ministry claimed to have shot down 36 Ukrainian drones, including two over Belgorod Oblast, four over Voronezh Oblast, nine over Lipetsk Oblast and two both over Oryol Oblast and Belgorod Oblasts. Fifteen drones were also downed over Kursk Oblast. There were no reports of damage or casualties.
The report that CMS requires labs to prominently display complaint posters instructing lab workers how to file anonymous complaints. In a July 2007 response to the GAO, CMS said that it lacked the legal authority to mandate labs to display posters. They plan to take several other steps to increase awareness of complaint processes including: (1) posting fact sheet on the CMS web site on complaint filing (2) adding information on filing complaints to the interpretive guidelines used by surveyors (3) adding complaints received by accrediting organizations to their complaints database and (4) reminding states and accrediting organizations by letter about the importance of complaints. CMS reported that it sent a letter about complaint tracking to accreditation organizations, exempt states, and professional laboratory organizations on November 30, 2007. According to CMS, this letter highlighted the importance of complaint tracking and filing, and encouraged the publication of compliant processes. CMS has also developed a CLIA Brochure on Complaints, which was being prepared for release as of September 2008. Once released, CMS anticipates posting the brochure on its website and printing copies for distribution to laboratories. We will continue to monitor the implementation of this recommendation. In 2009, the GAO recommended that CMS require all survey organizations to develop and require labs to prominently display posters instructing lab workers how to file anonymous complaints.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.